<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381833</url>
  </required_header>
  <id_info>
    <org_study_id>LJ401-BT01</org_study_id>
    <nct_id>NCT03381833</nct_id>
  </id_info>
  <brief_title>A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia</brief_title>
  <official_title>A Multi-Center, Randomized, Open-Label, Parallel-Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La Jolla Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La Jolla Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The&#xD;
      primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human&#xD;
      hepcidin) on iron levels in patients with transfusion-dependent beta thalassemia with&#xD;
      myocardial iron overload.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early for lack of efficacy as determined by interim endpoint analyses&#xD;
  </why_stopped>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Actual">January 14, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of LJPC-401 on cardiac iron</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in cardiac T2* magnetic resonance imaging (MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on cardiac iron</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in cardiac T2*MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on hepatic iron</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in hepatic T2*MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on serum iron</measure>
    <time_frame>56 Weeks</time_frame>
    <description>Mean change in serum iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on hemoglobin</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Mean change in hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on volume of blood transfused</measure>
    <time_frame>56 Weeks</time_frame>
    <description>Change in transfused blood volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on its potential to elicit an immune response</measure>
    <time_frame>56 Weeks</time_frame>
    <description>Measured by blood laboratory tests and the presence of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on the incidence of treatment-emergent adverse events</measure>
    <time_frame>56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on vital signs-heart rate</measure>
    <time_frame>56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on vital signs-body temperature</measure>
    <time_frame>56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on vital signs-respiratory rate</measure>
    <time_frame>56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on vital signs-blood pressure</measure>
    <time_frame>56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LJPC-401 on body weight</measure>
    <time_frame>56 Weeks</time_frame>
    <description>Change in body weight (kilograms)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>Group A - Delayed therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Immediate therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard chelation therapy plus LJPC-401 for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LJPC-401</intervention_name>
    <description>subcutaneous injection, up to 20 mg per week from week 26 to 52</description>
    <arm_group_label>Group A - Delayed therapy</arm_group_label>
    <other_name>synthetic human hepcidin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LJPC-401</intervention_name>
    <description>subcutaneous injection, up to 20 mg per week from week 1 to 52</description>
    <arm_group_label>Group B - Immediate therapy</arm_group_label>
    <other_name>synthetic human hepcidin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 14 years of age with transfusion-dependent beta thalassemia.&#xD;
&#xD;
          -  Patients must have increased iron levels in the heart as measured by magnetic&#xD;
             resonance imaging (MRI). Two separate cardiac T2*MRI from 6 to 35 msec; &lt;= 15%&#xD;
             difference between the two.&#xD;
&#xD;
          -  Patients must be receiving iron chelation therapy for a minimum of 1 year and be on a&#xD;
             stable dose prior to study and expected to remain stable during study.&#xD;
&#xD;
          -  Female patients of childbearing potential must not be pregnant, must have negative&#xD;
             pregnancy tests, and must use an effective birth control method during the study.&#xD;
&#xD;
          -  Male patients must be either surgically sterile or use an effective birth control&#xD;
             method during the study.&#xD;
&#xD;
          -  Patient must be willing and able to provide written informed consent. Parent of legal&#xD;
             guardian to patients younger than age of majority must be willing and able to provide&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant medical condition or lab abnormality that would prevent the patient&#xD;
             from participating in the study.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients taking an immunosuppressive agent (except topical over-the-counter steroids,&#xD;
             inhaled steroid medications, and non-steroidal anti-inflammatory drugs) or have a&#xD;
             planned surgery (except dental surgery or simple dermatologic procedures).&#xD;
&#xD;
          -  Patients participating in an unapproved investigational clinical trial within 30 days&#xD;
             of this study.&#xD;
&#xD;
          -  Patients with a disease, disability or condition which may interfere with the conduct&#xD;
             of the study, or which would, in the opinion of the Investigator, pose an unacceptable&#xD;
             risk to the patient.&#xD;
&#xD;
          -  Patients who are unwilling or unable to comply with the study requirements.&#xD;
&#xD;
          -  Patients with known hepatitis B or hepatitis C, or being treated for a positive viral&#xD;
             load or are noncompliant with hepatitis medications.&#xD;
&#xD;
          -  Known and active human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Patients with Child Pugh class C cirrhosis or liver failure.&#xD;
&#xD;
          -  Patients with severe congestive heart failure (NYHA Class 4).&#xD;
&#xD;
          -  Use of erythropoiesis stimulating agents in the past 3 months prior to study entry.&#xD;
&#xD;
          -  History of allergic reaction to hepcidin or excipients.&#xD;
&#xD;
          -  Contraindication to MRI scanning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Goudí</city>
        <state>Attica</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Thessaloníki</city>
        <state>Macedonia</state>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Patra</city>
        <state>Peloponnese</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok Noi</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07160</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <zip>N19 5NF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepcidins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

